Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Gains from Investment Securities (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Gains from Investment Securities data on record, last reported at $15.2 million in Q1 2025.

  • For Q1 2025, Gains from Investment Securities changed N/A year-over-year to $15.2 million; the TTM value through Mar 2025 reached $15.2 million, changed N/A, while the annual FY2024 figure was $11.6 million, 23.36% up from the prior year.
  • Gains from Investment Securities reached $15.2 million in Q1 2025 per GLUE's latest filing, up from $11.6 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $15.2 million in Q1 2025 and bottomed at -$131000.0 in Q1 2023.
  • Average Gains from Investment Securities over 3 years is $8.0 million, with a median of $10.5 million recorded in 2023.
  • The widest YoY moves for Gains from Investment Securities: up 23.36% in 2024, down 23.36% in 2024.
  • A 3-year view of Gains from Investment Securities shows it stood at $9.4 million in 2023, then rose by 23.36% to $11.6 million in 2024, then surged by 30.74% to $15.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $15.2 million in Q1 2025, $11.6 million in Q4 2024, and $11.5 million in Q2 2024.